Marshall Wace, LLP Biomea Fusion, Inc. Transaction History
Marshall Wace, LLP
- $74.4 Billion
- Q1 2025
A detailed history of Marshall Wace, LLP transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 28,466 shares of BMEA stock, worth $38,998. This represents 0.0% of its overall portfolio holdings.
Number of Shares
28,466
Previous 123,313
76.92%
Holding current value
$38,998
Previous $478,000
87.45%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding BMEA
# of Institutions
109Shares Held
16.1MCall Options Held
229KPut Options Held
354K-
Cormorant Asset Management, LP Boston, MA3.57MShares$4.89 Million0.81% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$3.21 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.38MShares$1.89 Million0.0% of portfolio
-
Aisling Capital Management LP New York, NY799KShares$1.09 Million0.59% of portfolio
-
Geode Capital Management, LLC Boston, MA626KShares$857,5550.0% of portfolio
About Biomea Fusion, Inc.
- Ticker BMEA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,290,600
- Market Cap $40.1M
- Description
- Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...